Thrombotic risk assessment and analytical performance of the chemiluminescent analyzer IDS-iSYS for the detection of anti-cardiolipin and anti-beta 2 glycoprotein I autoantibodies
| Autor: | Nafai Salma, Jousse-Joulin Sandrine, Bendaoud Boutahar, Lemerle Julie, Hillion Sophie, Le Ny Fabien, Couturaud Francis, Pasquier Elisabeth, Bettacchioli Eleonore, Renaudineau Yves, Le Nuz Sylvie |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
0301 basic medicine
Male Cardiolipins Immunology 030204 cardiovascular system & hematology Risk Assessment 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine Antiphospholipid syndrome Cardiolipin medicine Odds Ratio Immunology and Allergy Beta 2-Glycoprotein I Humans Autoantibodies biology business.industry Autoantibody Thrombosis Odds ratio Middle Aged musculoskeletal system medicine.disease Antiphospholipid Syndrome carbohydrates (lipids) Venous thrombosis 030104 developmental biology chemistry beta 2-Glycoprotein I Antibodies Anticardiolipin Immunoglobulin G Luminescent Measurements biology.protein Antibodies Antiphospholipid lipids (amino acids peptides and proteins) Female Antibody business |
| Zdroj: | Clinical immunology (Orlando, Fla.). 194 |
| ISSN: | 1521-7035 |
| Popis: | Patients with antiphospholipid antibodies (APLA) are predisposed to develop thrombosis, however the standardization of anti-cardiolipin (aCL) and anti-beta 2 glycoprotein I (β2-GPI) Ab assays are challenging. Therefore we decided to test the performance of a new chemiluminescent assay (CLIA), and assayed aCL and aβ2-GPI IgG/M in serum from 120 healthy individuals, 108 patients with idiopathic venous thrombosis, 78 patients with antiphospholipid syndrome (APS), and 64 non-thrombotic APLA-carriers using CLIA IDS-iSYS. Very good (aCL/aβ2-GPI IgG) to moderate (aCL/aβ2-GPI IgM) agreement with a commercial and an in house ELISA assay were observed and, in particular, CLIA demonstrated the highest sensitivity in aβ2-GPI IgG detection. Finally, aCL/aβ2-GPI Ab capacity to predict the thrombotic risk was tested showing for CLIA a significant odds ratio (OR) when considering double positivity for aCL/aβ2-GPI IgG, aCL IgG at high levels, and aβ2-GPI IgG at high levels. In conclusion, CLIA improves aβ2-GPI IgG detection and thrombotic risk assessment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect